Key Developments: Bioporto A/S (BIOPOR.CO)

BIOPOR.CO on Copenhagen Stock Exchange

2.40DKK
9:18am EDT
Price Change (% chg)

kr.0.02 (+0.84%)
Prev Close
kr.2.38
Open
kr.2.35
Day's High
kr.2.48
Day's Low
kr.2.35
Volume
254,317
Avg. Vol
395,682
52-wk High
kr.4.80
52-wk Low
kr.0.92

Search Stocks

Latest Key Developments (Source: Significant Developments)

BioPorto elects PWC as auditor
Thursday, 10 Apr 2014 05:48am EDT 

BioPorto A/S:Elects PWC as auditor for the company.  Full Article

EPO rules BioPorto NGAL cutoff-patent invalid
Tuesday, 1 Apr 2014 08:51am EDT 

BioPorto A/S:Says the European Patent Office (EPO) has decided that the company's NGAL cutoff patent no. EP1831699 does not meet the requirements for adequate description.Says the patent is thus ruled invalid.  Full Article

BioPorto issues FY 2014 guidance
Wednesday, 19 Mar 2014 12:23pm EDT 

BioPorto A/S:Expects to generate revenue of between 19 million Danish crowns and 23 million Danish crowns in 2014, equivalent to a growth rate of 15–40 percent in the fiscal year 2014.Expects a loss of between 10 million Danish crowns and 14 million Danish crowns in the fiscal year 2014.  Full Article

BioPorto announces settlement between the company and Phadia in patent case
Saturday, 1 Mar 2014 04:03am EST 

BioPorto A/S:Says the company and Phadia have reached a settlement in the case regarding the revocation of Phadia’s patent DK/EP 0756 708, which cites the use of HNL (another designation of NGAL) as a diagnostic marker of human illness.Along with the settlement, the company receives a worldwide license to Phadia’s patents in the NGAL area and achieves free market access for its portfolio of NGAL products.  Full Article

BioPorto enters intellectual property license agreement with Abbott
Saturday, 1 Mar 2014 03:49am EST 

BioPorto A/S:Enters agreement with Abbott to cross-license their respective NGAL intellectual property rights (IPR).The agreements are non-exclusive and cover all the NGAL related IPR directly and indirectly controlled by both parties – including sub-licenses from Phadia and Cincinnati Children’s Hospital.Terms of the agreements include upfront fees and royalties paid on sales for both parties.  Full Article

BioPorto A/S receives intention to grant for NGAL exclusion patent in Europe
Friday, 21 Feb 2014 02:50am EST 

BioPorto A/S:Says the European Patent Office has published intention to grant BioPorto’s patent no. EP2064553 regarding exclusion of acute kidney injury.Says the patent is part of BioPorto’s IP rights in the NGAL area and is complementary to the NGAL cutoff patent.  Full Article

BioPorto A/S Comments On FY 2013 Guidance
Friday, 8 Nov 2013 03:18am EST 

BioPorto A/S announced that for the fiscal year 2013, it expects to report revenue on a par with revenue reported for the fiscal year 2012. The Company has previously announced expectations for a loss of between DKK 18 million and DKK 21 million. With the additional costs related to the ongoing restructuring, the loss is expected to be at the upper end of the range.  Full Article

EPO Calls for Oral Proceedings in Appeal Case Concerning BioPorto A/S' NGAL Cutoff Patent EP1831699
Thursday, 7 Nov 2013 02:44am EST 

BioPorto A/S announced that the European Patent Organization (EPO) calls for oral proceedings on April 1, 2014 in the NGAL cutoff opposition proceedings.  Full Article

BioPorto A/S Announces Mr. Otto Rasmussen as New CFO
Wednesday, 30 Oct 2013 11:06am EDT 

BioPorto A/S announced that Mr. Otto Rasmussen has been appointed new Chief Financial Officer (CFO) of the Company as per January 1, 2014 and will be part of the executive management team. He replaces CFO Mr. Frank Harder, who resigned at his own request.  Full Article

EPO Defers Decision on Appeal Concerning BioPorto A/S’ NGAL Cutoff Patent EP1831699
Tuesday, 15 Oct 2013 01:12pm EDT 

BioPorto A/S announced that following a hearing in the NGAL cutoff opposition proceedings that took place on October 15, 2013, the European Patent Organization (EPO) has exceptionally chosen not to reach a final decision. The proceedings will be continued on the basis of written submissions. BioPorto has not received information about the timing of further proceedings. BioPorto’s patent remains fully valid during the proceedings.  Full Article

No consensus analysis data available.
Search Stocks